Palvella Therapeutics (PVLA) Total Current Liabilities (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Total Current Liabilities of $9.1 million for Q1 2026, up 1.47% year-over-year from $9.0 million in Q1 2025, and down 19.65% quarter-over-quarter from $11.3 million in Q4 2025.
Palvella Therapeutics (PVLA) Total Current Liabilities (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Total Current Liabilities for 14 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 1.47% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $9.1 million (up 1.47% YoY), while the FY2025 annual figure was $11.3 million, down 5.77% from the prior year.
- Total Current Liabilities eased to $9.1 million in Q1 2026 per PVLA's latest filing, from $11.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $42.9 million in Q1 2023 and bottomed at $2.4 million in Q4 2023.
- Historically, Total Current Liabilities has averaged $19.6 million across 5 years, with a median of $11.3 million in 2025.
- Annual changes were most pronounced in 2023 — Total Current Liabilities plunged 93.55% — and 2024, when it soared 410.08%.
- Palvella Therapeutics' Total Current Liabilities stood at $36.6 million in 2022, then slumped by 93.55% to $2.4 million in 2023, then jumped by 410.08% to $12.0 million in 2024, then dropped by 5.77% to $11.3 million in 2025, then declined by 19.65% to $9.1 million in 2026.
- Business Quant data shows PVLA's Total Current Liabilities at $9.1 million in Q1 2026, $11.3 million in Q4 2025, and $10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 11.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.95 Mn |
| Mar 31, 2026 | 9.12 Mn |
| Dec 31, 2025 | 11.34 Mn |
| Sep 30, 2025 | 10.31 Mn |
| Jun 30, 2025 | 9.62 Mn |
| Mar 31, 2025 | 8.98 Mn |
| Dec 31, 2024 | 12.04 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 6.35 Mn |
| Mar 31, 2024 | 7.53 Mn |
| Dec 31, 2023 | 2.36 Mn |
| Sep 30, 2023 | 28.87 Mn |
| Jun 30, 2023 | 34.37 Mn |
| Mar 31, 2023 | 42.88 Mn |
| Dec 31, 2022 | 36.58 Mn |
| Sep 30, 2022 | 33.52 Mn |
| Jun 30, 2022 | 35.55 Mn |
| Mar 31, 2022 | 39.48 Mn |
| Dec 31, 2021 | 50.56 Mn |
| Sep 30, 2021 | 49.70 Mn |